ABBOTT PARK, Ill., April 17, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2024.
"Our first-quarter results reflect a strong start to the year, and we are raising our full-year sales and EPS guidance," said Robert B. Ford, chairman and chief executive officer, Abbott. "This was the fifth consecutive quarter that we delivered double-digit organic sales growth in our underlying base business, which included particularly strong results in Medical Devices and Established Pharmaceuticals."
FIRST-QUARTER BUSINESS OVERVIEW
Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange, and the impact of the acquisition of Cardiovascular Systems, Inc. (CSI), is an appropriate way for investors to best understand the core underlying performance of the business. Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand underlying base business performance as the COVID-19 pandemic has shifted to an endemic state, resulting in significantly lower demand for COVID-19 tests.
Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
Total Company First Quarter 2024 Results (1Q24) | |||||||||
Sales 1Q24 ($ in millions) | Total Company | Nutrition | Diagnostics | Established | Medical Devices | ||||
U.S. | 3,846 | 878 | 931 | — | 2,034 | ||||
International | 6,118 | 1,190 | 1,283 | 1,226 | 2,419 | ||||
Total reported | 9,964 | 2,068 | 2,214 | 1,226 | 4,453 | ||||
% Change vs. 1Q23 | |||||||||
U.S. | (2.1) | 8.1 | (30.3) | n/a | 14.4 | ||||
International | 5.2 | 3.0 | (5.1) | 3.1 | 14.0 | ||||
Total reported | 2.2 | 5.1 | (17.6) | 3.1 | 14.2 | ||||
Impact of foreign exchange | (2.9) | (2.6) | (2.1) | (10.6) | (1.2) | ||||
Impact of CSI acquisition | 0.4 | — | — | — | 1.1 | ||||
Organic | 4.7 | 7.7 | (15.5) | 13.7 | 14.3 | ||||
Impact of COVID-19 testing sales | (6.1) | — | (20.9) | — | — | ||||
Organic (excluding COVID-19 tests) | 10.8 | 7.7 | 5.4 | 13.7 | 14.3 | ||||
U.S. | 10.0 | 8.1 | 7.0 | n/a | 12.1 | ||||
International | 11.3 | 7.4 | 4.4 | 13.7 | 16.1 | ||||
Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of adjusted historical revenue to reported revenue.
Nutrition
First Quarter 2024 Results (1Q24) | |||||
Sales 1Q24 ($ in millions) | Total | Pediatric | Adult | ||
U.S. | 878 | 514 | 364 | ||
International | 1,190 | 495 | 695 | ||
Total reported | 2,068 | 1,009 | 1,059 | ||
% Change vs. 1Q23 | |||||
U.S. | 8.1 | 12.0 | 3.0 | ||
International | 3.0 | 6.4 | 0.8 | ||
Total reported | 5.1 | 9.2 | 1.5 | ||
Impact of foreign exchange | (2.6) | (1.3) | (3.8) | ||
Organic | 7.7 | 10.5 | 5.3 | ||
U.S. | 8.1 | 12.0 | 3.0 | ||
International | 7.4 | 8.9 | 6.4 | ||
Worldwide Nutrition sales increased 5.1 percent on a reported basis and 7.7 percent on an organic basis in the first quarter.
In Pediatric Nutrition, global sales increased 9.2 percent on a reported basis and 10.5 percent on an organic basis. In the U.S., sales growth of 12.0 percent was primarily driven by market share gains in the infant formula business. International sales increased 6.4 percent on a reported basis and 8.9 percent on an organic basis, which was led by strong growth in Canada and several countries in Asia Pacific and Latin America.
In Adult Nutrition, global sales increased 1.5 percent on a reported basis and 5.3 percent on an organic basis, which was led by growth of Ensure®, Abbott's market-leading complete and balanced nutrition brand.
Diagnostics | |||||||||
First Quarter 2024 Results (1Q24) | |||||||||
Sales 1Q24 ($ in millions) | Total | Core Laboratory | Molecular | Point of Care | Rapid | ||||
U.S. | 931 | 310 | 42 | 98 | 481 | ||||
International | 1,283 | 895 | 87 | 41 | 260 | ||||
Total reported | 2,214 | 1,205 | 129 | 139 | 741 | ||||
% Change vs. 1Q23 | |||||||||
U.S. | (30.3) | 7.3 | (10.6) | 5.6 | (46.9) | ||||
International | (5.1) | 0.2 | (12.5) | (0.6) | (18.3) | ||||
Total reported | (17.6) | 2.0 | (11.9) | 3.7 | (39.5) | ||||
Impact of foreign exchange | (2.1) | (3.9) | (0.2) | 0.1 | (0.8) | ||||
Organic | (15.5) | 5.9 | (11.7) | 3.6 | (38.7) | ||||
Impact of COVID-19 testing sales | (20.9) | (0.3) | (10.9) | — | (44.3) | ||||
Organic (excluding COVID-19 tests) | 5.4 | 6.2 | (0.8) | 3.6 | 5.6 | ||||
U.S. | 7.0 | 7.7 | 6.2 | 5.6 | 6.9 | ||||
International | 4.4 | 5.7 | (3.6) | (0.8) | 3.5 | ||||
As expected, Diagnostics sales growth in the first quarter was negatively impacted by year-over-year declines in COVID-19 testing-related sales3. Worldwide COVID-19 testing sales were $204 million in the first quarter of 2024 compared to $730 million in the first quarter of the prior year.
Excluding COVID-19 testing-related sales, global Diagnostics sales increased 2.7 percent on a reported basis and 5.4 percent on an organic basis.
Excluding COVID-19 testing-related sales, global Core Laboratory Diagnostics sales increased 2.2 percent on a reported basis and 6.2 percent on an organic basis, led by continued strong adoption of Abbott's Alinity® family of diagnostics systems and testing portfolios.
Established Pharmaceuticals | |||||
First Quarter 2024 Results (1Q24) | |||||
Sales 1Q24 ($ in millions) | Total | Key Emerging | Other | ||
U.S. | — | — | — | ||
International | 1,226 | 928 | 298 | ||
Total reported | 1,226 | 928 | 298 | ||
% Change vs. 1Q23 | |||||
U.S. | n/a | n/a | n/a | ||
International | 3.1 | 1.7 | 7.6 | ||
Total reported | 3.1 | 1.7 | 7.6 | ||
Impact of foreign exchange | (10.6) | (13.7) | (0.6) | ||
Organic | 13.7 | 15.4 | 8.2 | ||
U.S. | n/a | n/a | n/a | ||
International | 13.7 | 15.4 | 8.2 | ||
Established Pharmaceuticals sales increased 3.1 percent on a reported basis and 13.7 percent on an organic basis in the first quarter.
Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 1.7 percent on a reported basis and 15.4 percent on an organic basis, led by growth in several geographies and therapeutic areas, including respiratory, women's health, and central nervous system/pain management.
Medical Devices | |||||||||||||||
First Quarter 2024 Results (1Q24) | |||||||||||||||
Sales 1Q24 ($ in millions) | Total | Rhythm | Electro- | Heart | Vascular | Structural | Neuro- | Diabetes | |||||||
U.S. | 2,034 | 271 | 269 | 237 | 254 | 233 | 181 | 589 | |||||||
International | 2,419 | 291 | 318 | 68 | 435 | 282 | 45 | 980 | |||||||
Total reported | 4,453 | 562 | 587 | 305 | 689 | 515 | 226 | 1,569 | |||||||
% Change vs. 1Q23 | |||||||||||||||
U.S. | 14.4 | 4.5 | 13.1 | 8.7 | 16.4 | 10.8 | 16.8 | 22.8 | |||||||
International | 14.0 | 9.0 | 18.9 | 7.7 | 9.1 | 12.5 | 9.8 | 17.6 | |||||||
Total reported | 14.2 | 6.8 | 16.2 | 8.5 | 11.7 | 11.7 | 15.3 | 19.5 | |||||||
Impact of foreign exchange | (1.2) | (0.7) | (2.2) | 0.1 | (1.0) | (1.3) | (2.1) | (1.2) | |||||||
Impact of CSI | 1.1 | — | — | — | 6.9 | — | — | — | |||||||
Organic | 14.3 | 7.5 | 18.4 | 8.4 | 5.8 | 13.0 | 17.4 | 20.7 | |||||||
U.S. | 12.1 | 4.5 | 13.1 | 8.7 | (1.8) | 10.8 | 16.8 | 22.8 | |||||||
International | 16.1 | 10.3 | 23.0 | 7.1 | 9.9 | 14.8 | 19.6 | 19.6 | |||||||
Worldwide Medical Devices sales increased 14.2 percent on a reported basis and 14.3 percent on an organic basis in the first quarter, including double-digit growth in both the U.S. and internationally.
Sales growth was led by double-digit growth in Diabetes Care, Electrophysiology, Neuromodulation, and Structural Heart. Several recently launched products and new indications contributed to the strong performance, including Amplatzer® Amulet®, Navitor®, TriClip®, and AVEIR®.
In Electrophysiology, internationally, sales grew 18.9 percent on a reported and 23.0 percent on an organic basis, which included organic sales growth of 20.4 percent in Europe.
In Diabetes Care, FreeStyle Libre sales were $1.5 billion, which represents sales growth of 22.4 percent on a reported basis and 23.3 percent on an organic basis.
ABBOTT'S EARNINGS-PER-SHARE GUIDANCE
Abbott projects full-year 2024 diluted earnings per share under GAAP of $3.25 to $3.40. Abbott forecasts specified items for the full-year 2024 of $1.30 per share primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share would be $4.55 to $4.70 for the full-year 2024.
Abbott projects second-quarter 2024 diluted earnings per share under GAAP of $0.69 to $0.73. Abbott forecasts specified items for the second-quarter 2024 of $0.39 per share primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share would be $1.08 to $1.12 for the second quarter 2024.
ABBOTT DECLARES 401ST CONSECUTIVE QUARTERLY DIVIDEND
On February 16, 2024, the board of directors of Abbott declared the company's quarterly dividend of $0.55 per share. Abbott's cash dividend is payable May 15, 2024, to shareholders of record at the close of business on April 15, 2024.
Abbott has increased its dividend payout for 52 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.
Abbott will live-webcast its first-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.
Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2023, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
1 | In the first quarter of 2024, total worldwide sales were $9.964 billion and COVID-19 testing-related sales were $204 million. In the first quarter of 2023, total worldwide sales were $9.747 billion and COVID-19 testing-related sales were $730 million. |
2 | Abbott has not provided the related GAAP financial measure for organic sales growth, excluding COVID-19 testing-related sales, on a forward-looking basis because the company is unable to predict with reasonable certainty the impact of foreign exchange due to the unpredictability of future changes in foreign exchange rates, which could significantly impact reported sales growth. In addition, as the COVID-19 pandemic has shifted to an endemic state, the company has determined that it is unable to predict with reasonable certainty future COVID-19 test sales due to the unpredictability of demand for COVID-19 tests. |
3 | Diagnostic sales and COVID-19 testing-related sales in 2024 and 2023 are summarized below: |
Sales 1Q24 | COVID Tests Sales 1Q24 | |||||||||||
($ in millions) | U.S. | Int'l | Total | U.S. | Int'l | Total | ||||||
Total Diagnostics | 931 | 1,283 | 2,214 | 153 | 51 | 204 | ||||||
Core Laboratory | 310 | 895 | 1,205 | 1 | 2 | 3 | ||||||
Molecular | 42 | 87 | 129 | 3 | 1 | 4 | ||||||
Rapid Diagnostics | 481 | 260 | 741 | 149 | 48 | 197 | ||||||
Sales 1Q23 | COVID Tests Sales 1Q23 | |||||||||||
($ in millions) | U.S. | Int'l | Total | U.S. | Int'l | Total | ||||||
Total Diagnostics | 1,335 | 1,353 | 2,688 | 608 | 122 | 730 | ||||||
Core Laboratory | 289 | 893 | 1,182 | 2 | 4 | 6 | ||||||
Molecular | 47 | 100 | 147 | 10 | 10 | 20 | ||||||
Rapid Diagnostics | 906 | 319 | 1,225 | 596 | 108 | 704 | ||||||
Abbott Laboratories and Subsidiaries Condensed Consolidated Statement of Earnings First Quarter Ended March 31, 2024 and 2023 (in millions, except per share data) (unaudited) | ||||||
1Q24 | 1Q23 | % Change | ||||
Net Sales | $9,964 | $9,747 | 2.2 | |||
Cost of products sold, excluding amortization expense | 4,463 | 4,331 | 3.0 | |||
Amortization of intangible assets | 472 | 491 | (3.9) | |||
Research and development | 684 | 654 | 4.5 | |||
Selling, general, and administrative | 2,959 | 2,762 | 7.1 | |||
Total Operating Cost and Expenses | 8,578 | 8,238 | 4.1 | |||
Operating Earnings | 1,386 | 1,509 | (8.1) | |||
Interest expense, net | 61 | 52 | 18.4 | |||
Net foreign exchange (gain) loss | — | 6 | (92.2) | |||
Other (income) expense, net | (111) | (111) | (0.4) | |||
Earnings before taxes | 1,436 | 1,562 | (8.1) | |||
Taxes on earnings | 211 | 244 | (13.7) | 1) | ||
Net Earnings | $1,225 | $1,318 | (7.0) | |||
Net Earnings excluding Specified Items, as described below | $1,729 | $1,815 | (4.7) | 2) | ||
Diluted Earnings per Common Share | $0.70 | $0.75 | (6.7) | |||
Diluted Earnings per Common Share, excluding Specified Items, as described below | $0.98 | $1.03 | (4.9) | 2) | ||
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options | 1,750 | 1,752 | ||||
NOTES: | |
See table tilted "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information. | |
n/m = Percent change is not meaningful. | |
See footnotes on the following section. | |
1) | 2024 Taxes on Earnings includes the recognition of approximately $10 million of net tax expense as a result of the resolution of various tax positions related to prior years. |
2023 Taxes on Earnings includes the recognition of approximately $22 million of net tax expense as a result of the resolution of various tax positions related to prior years. | |
2) | 2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $504 million, or $0.28 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and other net expenses. |
2023 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $497 million, or $0.28 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and other net expenses. | |
Abbott Laboratories and Subsidiaries Non-GAAP Reconciliation of Financial Information First Quarter Ended March 31, 2024 and 2023 (in millions, except per share data) (unaudited) | |||||
1Q24 | |||||
As Reported | Specified | As Adjusted | |||
Intangible Amortization | $ 472 | $ (472) | $ — | ||
Gross Margin | 5,029 | 518 | 5,547 | ||
R&D | 684 | (21) | 663 | ||
SG&A | 2,959 | (34) | 2,925 | ||
Other (income) expense, net | (111) | (26) | (137) | ||
Earnings before taxes | 1,436 | 599 | 2,035 | ||
Taxes on Earnings | 211 | 95 | 306 | ||
Net Earnings | 1,225 | 504 | 1,729 | ||
Diluted Earnings per Share | $ 0.70 | $ 0.28 | $ 0.98 | ||
Specified items reflect intangible amortization expense of $472 million and other net expenses of $127 million associated with restructuring actions, costs associated with acquisitions, investment impairment charges and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.
1Q23 | |||||
As Reported | Specified | As Adjusted | |||
Intangible Amortization | $ 491 | $ (491) | $ — | ||
Gross Margin | 4,925 | 520 | 5,445 | ||
R&D | 654 | (26) | 628 | ||
SG&A | 2,762 | (2) | 2,760 | ||
Earnings before taxes | 1,562 | 548 | 2,110 | ||
Taxes on Earnings | 244 | 51 | 295 | ||
Net Earnings | 1,318 | 497 | 1,815 | ||
Diluted Earnings per Share | $ 0.75 | $ 0.28 | $ 1.03 | ||
Specified items reflect intangible amortization expense of $491 million and other net expenses of $57 million associated with restructuring actions, costs associated with acquisitions and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.
A reconciliation of the first-quarter tax rates for 2024 and 2023 is shown below:
1Q24 | ||||||
($ in millions) | Pre-Tax Income | Taxes on Earnings | Tax Rate | |||
As reported (GAAP) | $ 1,436 | $ 211 | 14.7 % | 1) | ||
Specified items | 599 | 95 | ||||
Excluding specified items | $ 2,035 | $ 306 | 15.0 % | |||
1Q23 | ||||||
($ in millions) | Pre-Tax Income | Taxes on Earnings | Tax Rate | |||
As reported (GAAP) | $ 1,562 | $ 244 | 15.6 % | 2) | ||
Specified items | 548 | 51 | ||||
Excluding specified items | $ 2,110 | $ 295 | 14.0 % | |||
1) | 2024 Taxes on Earnings includes the recognition of approximately $10 million of net tax expense as a result of the resolution of various tax positions related to prior years. |
2) | 2023 Taxes on Earnings includes the recognition of approximately $22 million of net tax expense as a result of the resolution of various tax positions related to prior years. |
Abbott Laboratories and Subsidiaries Non-GAAP Revenue Reconciliation First Quarter Ended March 31, 2024 and 2023 ($ in millions) (unaudited) | |||||||||||||
1Q24 | 1Q23 | % Change vs. 1Q23 | |||||||||||
Non-GAAP | |||||||||||||
Abbott | Impact of CSI | Adjusted | Abbott | Impact of CSI | Adjusted | Reported | Adjusted | Organic | |||||
Total Company | 9,964 | (42) | 9,922 | 9,747 | — | 9,747 | 2.2 | 1.8 | 4.7 | ||||
U.S. | 3,846 | (40) | 3,806 | 3,928 | — | 3,928 | (2.1) | (3.1) | (3.1) | ||||
Intl | 6,118 | (2) | 6,116 | 5,819 | — | 5,819 | 5.2 | 5.1 | 9.9 | ||||
Total Medical Devices | 4,453 | (42) | 4,411 | 3,900 | — | 3,900 | 14.2 | 13.1 | 14.3 | ||||
U.S. | 2,034 | (40) | 1,994 | 1,778 | — | 1,778 | 14.4 | 12.1 | 12.1 | ||||
Intl | 2,419 | (2) | 2,417 | 2,122 | — | 2,122 | 14.0 | 13.9 | 16.1 | ||||
Vascular | 689 | (42) | 647 | 617 | — | 617 | 11.7 | 4.8 | 5.8 | ||||
U.S. | 254 | (40) | 214 | 218 | — | 218 | 16.4 | (1.8) | (1.8) | ||||
Intl | 435 | (2) | 433 | 399 | — | 399 | 9.1 | 8.4 | 9.9 | ||||
Abbott Laboratories and Subsidiaries Details of Specified Items First Quarter Ended March 31, 2024 (in millions, except per share data) (unaudited) | |||||||||
Acquisition or Divestiture- related (a) | Restructuring and Cost Reduction Initiatives (b) | Intangible Amortization | Other (c) | Total Specifieds | |||||
Gross Margin | $ 1 | $ 42 | $ 472 | $ 3 | $ 518 | ||||
R&D | (3) | (2) | — | (16) | (21) | ||||
SG&A | (14) | (9) | — | (11) | (34) | ||||
Other (income) expense, net | 12 | — | — | (38) | (26) | ||||
Earnings before taxes | $ 6 | $ 53 | $ 472 | $ 68 | 599 | ||||
Taxes on Earnings (d) | 95 | ||||||||
Net Earnings | $ 504 | ||||||||
Diluted Earnings per Share | $ 0.28 | ||||||||
The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information." | |
a) | Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions. |
b) | Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. |
c) | Other includes various investment impairment charges and incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products. |
d) | Reflects the net tax benefit associated with the specified items. |
Abbott Laboratories and Subsidiaries Details of Specified Items First Quarter Ended March 31, 2023 (in millions, except per share data) (unaudited) | |||||||||
Acquisition or Divestiture- related (a) | Restructuring and Cost Reduction Initiatives (b) | Intangible Amortization | Other (c) | Total Specifieds | |||||
Gross Margin | $ 5 | $ 21 | $ 491 | $ 3 | $ 520 | ||||
R&D | (4) | 1 | — | (23) | (26) | ||||
SG&A | (4) | (4) | — | 6 | (2) | ||||
Other (income) expense, net | (6) | — | — | 6 | — | ||||
Earnings before taxes | $ 19 | $ 24 | $ 491 | $ 14 | 548 | ||||
Taxes on Earnings (d) | 51 | ||||||||
Net Earnings | $ 497 | ||||||||
Diluted Earnings per Share | $ 0.28 | ||||||||
The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information." | |
a) | Acquisition-related expenses include legal and other costs related to business acquisitions as well as integration costs, which represent incremental costs directly related to integrating acquired businesses. |
b) | Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. |
c) | Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products. |
d) | Reflects the net tax benefit associated with the specified items. |
| Last Trade: | US$113.37 |
| Daily Change: | -1.08 -0.94 |
| Daily Volume: | 3,076,701 |
| Market Cap: | US$197.260B |
October 24, 2024 October 16, 2024 October 10, 2024 September 05, 2024 September 04, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
